Company profile for Arbutus Biopharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Arbutus Biopharma Corporation (NASDAQ: ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with complementary mechanisms of action that we believe will result in a combination therapy that will trans...
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with complementary mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
701 Veterans Circle Warminster, Pennsylvania
Telephone
Telephone
+ 267-469-0914
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/13/3187194/14025/en/Arbutus-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/10/07/3162436/14025/en/Arbutus-Announces-Four-Abstracts-Accepted-for-Presentation-at-AASLD-The-Liver-Meeting-2025.html

GLOBENEWSWIRE
07 Oct 2025

https://www.globenewswire.com/news-release/2025/08/06/3128229/14025/en/Arbutus-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
06 Aug 2025

https://www.fiercebiotech.com/biotech/arbutus-regains-china-rights-potential-functional-hep-b-cure-part-strategic-rethink

FIERCE BIOTECH
25 Jun 2025

https://www.globenewswire.com/news-release/2025/06/25/3104977/14025/en/Arbutus-Reacquires-Greater-China-Rights-to-Imdusiran-and-Announces-Scientific-Advisory-Board-with-Late-Stage-Clinical-Focus.html

GLOBENEWSWIRE
25 Jun 2025

https://www.globenewswire.com/news-release/2025/05/14/3081038/14025/en/Arbutus-Reports-First-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
14 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty